{
  "docId": "019dd923-5e88-73ef-bd5a-2e760724f3df",
  "docSlug": "6d3545a6c010d7cb",
  "documentTitle": "Eyepoint Goldman Sachs June 10 2025",
  "authorId": "GoldmanSachs",
  "authorName": "EyePoint Pharmaceuticals",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "equity_research",
  "sourceTypeLabel": "Equity research",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 11,
  "pageCount": 29,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "business_case",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a four-column layout to present strategic advantages.",
  "elementsJson": [
    "headline_text",
    "bullet_list",
    "other"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5e88-73ef-bd5a-2e760724f3df/11",
  "deckHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df",
  "deckJsonHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df.json",
  "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.4,
        "y": 0.94
      },
      "kind": "disclaimer",
      "text": "wet AMD, wet age-related macular degeneration; EOP2, End of Phase 2; NI, noninferiority",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b6cba617-dce9-4a64-b6c5-bb389e68c075",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.22,
        "x": 0.04,
        "y": 0.285
      },
      "kind": "list",
      "text": "ESTABLISHED FDA APPROVAL PATH: Last four FDA approvals followed the noninferiority pathway; Recent superiority trial failure",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4c6234b3-f0a8-4a64-b036-8379eb9371ec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.22,
        "x": 0.27,
        "y": 0.285
      },
      "kind": "list",
      "text": "COMPLETED ROBUST PHASE 2 TRIAL: Derisked and informed Phase 3; Statistically non-inferior to “on-label” aflibercept in tough to treat population",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7153860b-ca22-4f9a-bb6f-d02232efd981",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.22,
        "x": 0.75,
        "y": 0.285
      },
      "kind": "list",
      "text": "PATIENT-FOCUSED APPROACH: Real-world trial design measured against on-label standard of care; All patients receive treatment with the goal of maintaining vision",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "be0527f6-14da-4130-bd61-5ef86428aaf0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.22,
        "x": 0.51,
        "y": 0.285
      },
      "kind": "list",
      "text": "PROACTIVE FDA INTERACTION: Formal EOP2 and Type C meetings; Written alignment on NI trial design and -4.5 NI margin",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cf5b6ccf-8212-48e5-a797-ef5502ce0dcd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "DURAVYU De-Risked Clinical Approach in Wet AMD",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c0c722a4-b6df-469d-a2c6-08d9dfb999c2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "16b35044-1291-4030-9fd7-0dc21a77835c",
      "evidence": "list/bullet: PATIENT-FOCUSED APPROACH: Real-world trial design measured against on-label standard of care; All patients receive treatment with the goal of maintaining vision",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}